Total Funding
3
Total FundingSeries B raised
Growth Score
pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
610385
Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases.
Acquired by 
Johnson & Johnson
Leonid Beigelman: Founder, Chief Scientific OfficerPast Role: InterMune, VP Medicinal Chemistry and Technical Operations- Cheng Kao: Senior Research FellowPast Role: Indiana University Bloomington, Professor, Molecular and Cellular Biochemistry
About the Company
Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ). This complementary group of platform
technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS).
